Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Tau antisense oligonucleotide

NIO752

An investigational treatment for Progressive Supranuclear Palsy.

Phase 3by Novartis
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Drug facts

The same compound appears under different names depending on the context. Here is how to identify NIO752 wherever you encounter it, plus the key facts at a glance.

Generic name
NIO752
Development code
NIO752
Drug class
Tau antisense oligonucleotide
Manufacturer
Novartis
How it's taken
Injection into the spinal fluid through the lower back, in a trial only

An investigational antisense medicine from Novartis, given by injection into the fluid around the spinal cord, designed to lower how much tau brain cells make, the protein that builds up in progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD)[6][8].

  • NIO752 is in a Phase 3 trial for PSP Richardson syndrome that began on June 3, 2026, and in a Phase 2 study for other forms of PSP, corticobasal syndrome and inherited MAPT-related frontotemporal degeneration that ClinicalTrials.gov lists as not yet recruiting[1][2].
  • No results showing whether NIO752 slows either disease have been published.
Follow NIO752 by email

We'll email you when the FDA acts on NIO752 and when new trials for Progressive Supranuclear Palsy open. Unsubscribe anytime.

You'll get, for Progressive Supranuclear Palsy:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Where NIO752 fits

NIO752 is an experimental tau-lowering antisense medicine from Novartis, given by injection into the spinal fluid, now in a Phase 3 trial for PSP Richardson syndrome and a Phase 2 study that includes other PSP forms and corticobasal syndrome[1][2].

  • No treatment delays or stops PSP from getting worse, according to Novartis's Phase 1 results summary[6].
  • NORD says there is no specific treatment for slowing corticobasal degeneration and describes only treatments for symptoms[11].
  • Other approaches aimed at tau are being tested in separate trials listed on the PSP and CBD disease pages.
  • NIO752 has not been compared with any other treatment, and no results on whether NIO752 slows PSP or CBD have been published[1][6].
  • A question to bring to a movement disorders specialist is which form of PSP or corticobasal syndrome a person has, since the Phase 3 and Phase 2 studies enroll different forms.

How NIO752 works

Tau is a normal brain protein that helps build and steady microtubules, the internal tracks that help nerve cells keep their shape and move materials around, according to MedlinePlus Genetics[9]. In PSP, defective tau gathers into abnormal clumps inside nerve cells and other brain cells, which is why PSP is grouped with the tauopathies[10].

NORD says abnormal levels of tau also build up in certain brain cells in corticobasal degeneration and eventually cause those cells to deteriorate[11]. NIO752 is an antisense oligonucleotide, a short man-made strand of genetic material, and CurePSP describes it as designed to interfere with the step in which tau's messenger RNA is turned into tau protein, which should lower tau levels[8].

Novartis describes NIO752 as a trial drug designed to block cells from making tau proteins[6]. Novartis's Phase 1 results summary does not report how much NIO752 lowered tau, and tau in the spinal fluid is one of the measures in the Phase 3 trial[6][1].

Clinical trial results

The Phase 3 trial (NCT07498426), which CurePSP calls PRESERVE, plans to enroll about 300 adults with mild to moderate PSP Richardson syndrome, the classic form of PSP, and assigns them by chance to NIO752 or placebo in a 2 to 1 ratio, with neither participants nor their doctors knowing which[1][7][8]. Its main measure is the change after 72 weeks on the mPSPRS-10, a 10-item rating of walking, limb function and speech and swallowing scored from 0 to 30, where higher scores mean more disability[1].

Other measures include daily activities, quality of life, thinking tests, brain volume on MRI and spinal fluid tau and neurofilament light, a marker of nerve damage[1]. People who finish the blinded part are offered NIO752 in an open-label extension[7]. The trial began on June 3, 2026, and ClinicalTrials.gov lists a primary completion date of July 2029[1].

The Phase 2 study (NCT07868328) is a basket study planned for 48 people in 3 cohorts: PSP forms other than Richardson syndrome, corticobasal syndrome not caused by Alzheimer's disease, and carriers of a disease-causing MAPT gene variant with frontotemporal lobar degeneration[2]. Each cohort is randomized to NIO752 or placebo in a blinded period, followed by an open-label extension in which everyone gets NIO752[2].

Its main measure is side effects through week 48, and other measures include a marker of whether the drug reaches its target and a marker of nerve damage[2]. ClinicalTrials.gov lists the study as not yet recruiting, with an estimated start date of October 23, 2026, a primary completion date of March 2029 and no sites posted as of November 14, 2026[2].

The completed Phase 1 study (NCT04539041) tested 6 dose groups against placebo in 59 people with PSP from February 2021 to October 2024 and was designed to check safety, not benefit[3][6]. Novartis has also tested a single injection of NIO752 in early Alzheimer's disease (NCT05469360), measuring spinal fluid tau at about 3 months, and University College London leads a study with Washington University in St. Louis measuring how much NIO752 slows tau production in Alzheimer's disease (NCT06372821)[4][5]. Results of those 2 studies have not been posted.

Main registered trial: NCT07498426 on ClinicalTrials.gov. Check it for the current status, sites and contacts before asking about enrollment.

Side effects and safety

Early trial safety observations

In the Phase 1 study in 59 people with PSP, 58 had at least 1 adverse event, a term that covers any medical problem during a trial whether or not the drug caused it[6]. Serious adverse events happened in 15 of the 45 people given NIO752 and in 7 of the 14 given placebo[6]. Encephalopathy, a change in how the brain works that can affect thinking, memory, mood and balance, was reported as a serious event in 2 people given NIO752, in the groups Novartis calls Dose D and Dose E1, and in no one on placebo[6].

Novartis reports that 2 people given NIO752 left the study because of an adverse event, and that 2 people died during the study, 1 in a NIO752 group and 1 on placebo[6]. People given NIO752 had higher signs of inflammation in the spinal fluid, such as white blood cells, than people on placebo about 1 year after starting, and Novartis concluded there were some safety concerns at certain doses[6].

Thoughts of suicide were checked and were about the same with NIO752 as with placebo[6]. Novartis has not published the dose amounts. Side effects are the main measure of the Phase 2 study, and they are also tracked in the Phase 3 trial[2][1].

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking NIO752

Given as an intrathecal injection, through a thin needle placed in the lower back into the fluid around the spinal cord, in trials only[6]. In the Phase 1 PSP study each person was planned to receive 4 injections of NIO752 or placebo over a treatment period of up to about 9 months, in 1 of 6 dose groups[6]. Novartis has not published the dose or the injection schedule used in the Phase 3 or Phase 2 studies. Any approved dose would be set by an FDA label.

Development history

Novartis registered the first NIO752 study, a Phase 1 trial in PSP, on ClinicalTrials.gov in September 2020, and it ran from February 2021 to October 2024[3][6]. The early Alzheimer's study began in February 2023, and the tau production study led by University College London began in November 2024[4][5]. When Novartis wrote its Phase 1 results summary, it said it planned future NIO752 trials in conditions related to tau[6].

The Phase 3 PSP trial was first posted on March 27, 2026 and began on June 3, 2026, and CurePSP shared an update from Novartis on the trial on May 7, 2026[1][8]. The Phase 2 study in PSP, corticobasal syndrome and MAPT-related disease was first posted on October 9, 2026[2].

Access and eligibility

Manufacturer
Novartis
Eligibility requirement

Not approved, and available only in a trial. The Phase 3 trial takes adults aged 41 to 81 with mild to moderate probable or possible PSP Richardson syndrome whose symptoms began less than 5 years ago, a PSPRS score under 40, a score of 20 or more on the Mini Mental State Examination thinking test, the ability to take at least 10 steps with little help, and a study partner who spends at least 5 hours a week with them[1]. ClinicalTrials.gov lists 9 recruiting US sites, in Scottsdale, San Francisco, Englewood (Colorado), Boca Raton, Jacksonville, Lexington (Kentucky), New Orleans, Rochester (Minnesota) and Round Rock (Texas), among 64 sites in 12 countries[1]. The Phase 2 study takes adults aged 41 to 81 whose symptoms began within the past 5 years, including people with corticobasal syndrome who meet the 2013 consensus criteria for possible or probable CBD and people with PSP forms other than Richardson syndrome, and it has no sites posted yet[2]. Both studies leave out people who cannot safely have a lumbar puncture, and the Phase 2 study also leaves out people taking blood thinners or antiplatelet medicines other than low-dose aspirin (100mg a day or less) or ibuprofen (600mg a day or less), unless a hematologist judges a pause for the procedure safe[1][2].

Access program details are provided for informational purposes and may vary based on insurance coverage, geographic location, and individual circumstances. Confirm current eligibility directly with the manufacturer or your specialty pharmacy.

Ask anything about NIO752
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Start withor ask

Explore Progressive Supranuclear Palsy trials

Common questions about NIO752

▸What is NIO752?

An investigational antisense medicine from Novartis, given by injection into the fluid around the spinal cord, designed to lower how much tau brain cells make, the protein that builds up in progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD)[6][8]. NIO752 is in a Phase 3 trial for PSP Richardson syndrome that began on June 3, 2026, and in a Phase 2 study for other forms of PSP, corticobasal syndrome and inherited MAPT-related frontotemporal degeneration that ClinicalTrials.gov lists as not yet recruiting[1][2]. No results showing whether NIO752 slows either disease have been published.

▸How does NIO752 work?

Tau is a normal brain protein that helps build and steady microtubules, the internal tracks that help nerve cells keep their shape and move materials around, according to MedlinePlus Genetics[9]. In PSP, defective tau gathers into abnormal clumps inside nerve cells and other brain cells, which is why PSP is grouped with the tauopathies[10]. NORD says abnormal levels of tau also build up in certain brain cells in corticobasal degeneration and eventually cause those cells to deteriorate[11]. NIO752 is an antisense oligonucleotide, a short man-made strand of genetic material, and CurePSP describes it as designed to interfere with the step in which tau's messenger RNA is turned into tau protein, which should lower tau levels[8]. Novartis describes NIO752 as a trial drug designed to block cells from making tau proteins[6]. Novartis's Phase 1 results summary does not report how much NIO752 lowered tau, and tau in the spinal fluid is one of the measures in the Phase 3 trial[6][1].

▸What are the side effects of NIO752?

In the Phase 1 study in 59 people with PSP, 58 had at least 1 adverse event, a term that covers any medical problem during a trial whether or not the drug caused it[6]. Serious adverse events happened in 15 of the 45 people given NIO752 and in 7 of the 14 given placebo[6]. Encephalopathy, a change in how the brain works that can affect thinking, memory, mood and balance, was reported as a serious event in 2 people given NIO752, in the groups Novartis calls Dose D and Dose E1, and in no one on placebo[6]. Novartis reports that 2 people given NIO752 left the study because of an adverse event, and that 2 people died during the study, 1 in a NIO752 group and 1 on placebo[6]. People given NIO752 had higher signs of inflammation in the spinal fluid, such as white blood cells, than people on placebo about 1 year after starting, and Novartis concluded there were some safety concerns at certain doses[6]. Thoughts of suicide were checked and were about the same with NIO752 as with placebo[6]. Novartis has not published the dose amounts. Side effects are the main measure of the Phase 2 study, and they are also tracked in the Phase 3 trial[2][1].

▸How is NIO752 taken?

Given as an intrathecal injection, through a thin needle placed in the lower back into the fluid around the spinal cord, in trials only[6]. In the Phase 1 PSP study each person was planned to receive 4 injections of NIO752 or placebo over a treatment period of up to about 9 months, in 1 of 6 dose groups[6]. Novartis has not published the dose or the injection schedule used in the Phase 3 or Phase 2 studies. Any approved dose would be set by an FDA label.

▸Is NIO752 FDA approved?

NIO752 is currently in phase 3 clinical trials for Progressive Supranuclear Palsy. It has not yet received FDA approval.

▸Is NIO752 FDA approved?

No. NIO752 is an experimental medicine in a Phase 3 trial for PSP and a Phase 2 study that includes corticobasal syndrome, and the FDA has not approved it for any use.

Maker: Novartis.

How it is given: By injection into the fluid around the spinal cord, through a thin needle in the lower back.

Source: ClinicalTrials.gov NCT07498426

▸Who can join the NIO752 Phase 3 trial for PSP?

Adults aged 41 to 81 with mild to moderate PSP Richardson syndrome whose symptoms began less than 5 years ago.

Other rules: A PSPRS score under 40, a Mini Mental State Examination score of 20 or more, able to take 10 steps with little help, and a study partner.

Where: 9 recruiting US sites in Arizona, California, Colorado, Florida, Kentucky, Louisiana, Minnesota and Texas, plus sites in 11 other countries.

Source: ClinicalTrials.gov NCT07498426

▸Is there a NIO752 trial for corticobasal degeneration?

Yes. A Novartis Phase 2 study (NCT07868328) has a cohort for corticobasal syndrome not caused by Alzheimer's disease.

Status: Not yet recruiting, with no sites posted as of November 14, 2026.

Ages: 41 to 81, with symptoms that began within the past 5 years.

Main measure: Side effects through week 48.

Source: ClinicalTrials.gov NCT07868328

▸Does NIO752 work for PSP?

Not known yet. No results showing whether NIO752 slows PSP have been published.

Phase 1: The first study checked safety in 59 people with PSP, and Novartis reported some safety concerns at certain doses and more spinal fluid inflammation than with placebo.

What is measured now: The Phase 3 trial tracks the change on a 10-item PSP rating scale after 72 weeks.

Timing: ClinicalTrials.gov lists a primary completion date of July 2029.

Source: Novartis Phase 1 results summary

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

  1. ClinicalTrials.gov. A Phase III, Randomized, Placebo-controlled, Parallel Group, Double-blind Study to Evaluate the Efficacy and Safety of NIO752 in Participants With Progressive Supranuclear Palsy Followed by an Open Label Extension. https://clinicaltrials.gov/study/NCT07498426
  2. ClinicalTrials.gov. A Phase II, Randomized, Double Blind, Placebo-controlled, Basket Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Participants With Primary Tauopathies. https://clinicaltrials.gov/study/NCT07868328
  3. ClinicalTrials.gov. A Randomized, Participant, Investigator and Sponsor Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intrathecally Administered NIO752 in Participants With Progressive Supranuclear Palsy. https://clinicaltrials.gov/study/NCT04539041
  4. ClinicalTrials.gov. A Randomized, Participant and Investigator Blinded, Placebo-Controlled Study to Evaluate the Ability of a Single Intrathecally Administered Dose of NIO752 to Lower Cerebrospinal Fluid Total Tau Levels in Participants With Early Alzheimer's Disease. https://clinicaltrials.gov/study/NCT05469360
  5. ClinicalTrials.gov. A Randomized, Participant & Investigator Blinded, Placebo-Controlled Study to Evaluate the Ability of Intrathecally Administered NIO752 to Lower CSF Total Tau Synthesis in Participants With AD Measured by Stable Isotope Labelling Kinetics. https://clinicaltrials.gov/study/NCT06372821
  6. Novartis. Clinical Trial Results Summary: A clinical trial to learn about the safety of NIO752 in people with progressive supranuclear palsy (CNIO752A02101). https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=2903
  7. Novartis. A Phase III, Randomized, Placebo-controlled, Parallel Group, Double-blind Study to Evaluate the Efficacy and Safety of NIO752 in Participants With Progressive Supranuclear Palsy Followed by an Open Label Extension. https://www.novartis.com/clinicaltrials/study/nct07498426
  8. CurePSP · 2026-05-07. Novartis Provides Update on PRESERVE, a Phase 3 Clinical Trial to evaluate NIO752 in PSP. https://www.psp.org/news/details/novartis-provides-update-on-preserve-a-phase-3-clinical-trial-to-evaluate-nio752-in-psp
  9. MedlinePlus, National Library of Medicine. MAPT gene: MedlinePlus Genetics. https://medlineplus.gov/genetics/gene/mapt/
  10. MedlinePlus, National Library of Medicine. Progressive supranuclear palsy: MedlinePlus Genetics. https://medlineplus.gov/genetics/condition/progressive-supranuclear-palsy/
  11. National Organization for Rare Disorders. Corticobasal Degeneration - Symptoms, Causes, Treatment | NORD. https://rarediseases.org/rare-diseases/corticobasal-degeneration/

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: November 2026.

Follow NIO752 by email

We'll email you when the FDA acts on NIO752 and when new trials for Progressive Supranuclear Palsy open. Unsubscribe anytime.

You'll get, for Progressive Supranuclear Palsy:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site